All In MedTech

Device Trial Radar · NCT04090424

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingTitle says "pivotal". Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 21, 2021

Primary completion

May 30, 2026

Study completion Dec 2026

Sponsor

Lead sponsor
PolyNovo Biomaterials Pty Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Sep 16, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).

Conditions

  • Burns

Interventions

  • NovoSorb BTMDevice

    NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.

  • Standard of CareProcedure

    Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of study lesions in both groups with complete wound closure after skin graftingTime frame: 4 weeks after skin grafting

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Valleywise Health

    Phoenix, Arizona

  • Southern California Regional Burn Center at LAC+USC

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.